力生制药(002393) - 2016 Q2 - 季度财报

Financial Performance - The company reported a revenue of CNY 457,528,993.43 for the first half of 2016, a decrease of 1.32% compared to the same period last year[19]. - Net profit attributable to shareholders was CNY 69,281,599.72, down 34.93% year-on-year[19]. - The total profit for the period was CNY 8,061,130, a decrease of 33.90% compared to the previous year[29]. - The company's revenue for the reporting period was approximately ¥457.53 million, a decrease of 1.32% compared to the same period last year[30]. - The operating profit for the first half of 2016 was CNY 78.70 million, compared to CNY 120.93 million in the previous year, indicating a decrease of about 34.9%[130]. - The total operating revenue for the current period was CNY 457,528,993.43, a decrease of 1.4% compared to CNY 463,636,353.34 in the previous period[129]. - The net profit attributable to the parent company was CNY 69.28 million, down from CNY 106.48 million, reflecting a decrease of approximately 34.8%[131]. - The total profit for the first half of 2016 was CNY 80.61 million, down from CNY 121.96 million, reflecting a decrease of about 33.9%[130]. Cash Flow - The net cash flow from operating activities was CNY 30,966,661.15, representing a decline of 65.45% compared to the previous year[19]. - The net cash flow from operating activities decreased by 65.45% to approximately ¥30.97 million, primarily due to a reduction in cash received from sales[30]. - The net cash flow from operating activities was -5,923,420.37 CNY, a significant decrease compared to 59,309,816.46 CNY in the previous period[141]. - The net cash flow from investing activities was -147,436,077.28 CNY, worsening from -97,586,744.06 CNY[141]. - The net cash flow from financing activities was -73,070,567.21 CNY, compared to -55,261,971.35 CNY in the previous period[142]. - The company reported a significant increase in cash outflow from investment activities, which rose by 39.27% to approximately ¥160.09 million due to increased external investments[30]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,404,000,144.99, a slight decrease of 0.16% from the end of the previous year[19]. - The net assets attributable to shareholders were CNY 2,967,605,923.26, down 0.08% from the previous year[19]. - Total liabilities were CNY 436,394,221.73, down from CNY 439,502,060.93[122]. - The company's total liabilities were CNY 1,430.43 million, indicating a stable leverage ratio[148]. Investments and Fundraising - Total fundraising amount reached ¥2,007,698,700, with ¥738,018 invested during the reporting period[51]. - Cumulative investment of fundraising amounts to ¥1,891,641,900, representing 94.2% of total funds raised[51]. - The company has invested CNY 6,501.28 million in the expansion project, achieving 76.36% of the planned investment by June 30, 2016[58]. - The company acquired 48% equity in a biochemical pharmaceutical company for ¥3,536,400, achieving a 100% completion rate[53]. Dividends and Shareholder Information - The company did not declare any cash dividends or bonus shares for this reporting period[5]. - The company implemented a cash dividend plan in 2016, distributing CNY 4.00 per 10 shares, totaling CNY 72.98 million[66]. - The total number of ordinary shareholders at the end of the reporting period was 20,807[108]. - The largest shareholder, Tianjin Jinhao Pharmaceutical Co., Ltd., holds 51.36% of the shares, totaling 93,710,608 shares[108]. Operational Developments - The company completed its overall relocation and commenced production in the new facility during the reporting period[28]. - The company emphasized innovation-driven strategies and structural adjustments to achieve its annual targets[28]. - The company has initiated a drug consistency evaluation project and is actively advancing new product development according to the established annual plan[34]. - The company has strengthened its marketing strategies, resulting in an increase in product bidding success across 17 provinces compared to the previous round[32]. Compliance and Governance - The company has established a governance structure that complies with the Company Law and relevant regulations, ensuring transparency and accountability[73]. - There were no significant litigation or arbitration matters during the reporting period[74]. - The company did not undergo any bankruptcy reorganization during the reporting period[75]. - The company has not engaged in any entrusted financial management or derivative investments during the reporting period[48][49]. Financial Reporting and Accounting - The half-year financial report has not been audited[100]. - The company’s financial statements are prepared based on the assumption of continuous operation, following the relevant accounting standards[162]. - The company’s financial statements comply with accounting standards and accurately reflect its financial position as of June 30, 2016, and its operating results for the first half of 2016[175]. - The company uses the Chinese Yuan as its functional currency for financial reporting, reflecting its primary economic environment[178].